T. Bakker
Risk assessmentInternal medicineRheumatologyMedDRAVedolizumabInfliximabEtanerceptRheumatoid arthritisDiscontinuationDepression (differential diagnoses)Adverse drug reactionPopulationDrug reactionIn patientLow dose methotrexateFamily medicineClinical trialMedicine
Publications 2
#1J. Van LintH-Index: 1
#2T. BakkerH-Index: 1
Last. Naomi T. JessurunH-Index: 6
view all 5 authors...
Background: Chronic fatigue is a well-known symptom in patients with rheumatic diseases and other immune-mediated inflammatory diseases (IMIDs). Therefore, fatigue as an adverse drug reaction (ADR) to biologics may remain unrecognised or may erroneously be attributed to the disease. Objectives: To assess patient-reported fatigue attributed to biologics for IMIDs and investigate predisposing factors of patient-reported fatigue. Methods: The Dutch Biologic Monitor is a multicenter patient-reported...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.